Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Kathryn C. Arbour, Laura Mezquita, Niamh Long, Hira Rizvi, Edouard Auclin, Andy Ni, Gala Martinez-Bernal, Roberto Ferrara, W. Victoria Lai, Lizza E. L. Hendriks, Joshua K. Sabari, Caroline Caramella, Andrew J. Plodkowski, Darragh Halpenny, Jamie E. Chaft, David Planchard, Gregory J. Riely, Benjamin Besse, Matthew D. Hellmann

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2872-2878
Number of pages12
JournalJournal of Clinical Oncology
Volume36
Issue number28
DOIs
Publication statusPublished - 1 Oct 2018

Keywords

  • ADVERSE EVENTS
  • DOUBLE-BLIND
  • OPEN-LABEL
  • T-CELLS
  • DYSPNEA
  • PEMBROLIZUMAB
  • DEXAMETHASONE
  • DOCETAXEL
  • FATIGUE

Cite this

Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martinez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., Sabari, J. K., Caramella, C., Plodkowski, A. J., Halpenny, D., Chaft, J. E., Planchard, D., Riely, G. J., Besse, B., & Hellmann, M. D. (2018). Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 36(28), 2872-2878. https://doi.org/10.1200/JCO.2018.79.0006